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Kong SLE patients compared to standard care. METHODS: A lifetime 
microsimulation model was adapted with epidemiological and cost data from 
Hong Kong. The model compares the use of belimumab against standard care 
and incorporates the BLISS-52 and BLISS-76 trial data for the short term 
outcomes within one year, while long-term outcomes were based on a natural 
history model developed using the Johns Hopkins Lupus registry. The natural 
history model describes the relationship between disease activity and other 
covariates on the risk of dying and developing organ damage. Data available 
from the SLE population in Hong Kong was used as input in the modified model. 
The analysis was performed from a Hong Kong health-care perspective. In the 
base case, cost and effectiveness were discounted to the year of analysis at 5% 
p.a. RESULTS: The base case analysis showed that compared to standard care, 
treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) 
and QALY by 0.60 (1.68 undiscounted) years respectively. Total incremental costs 
were US$47,865 (US$80,460 undiscounted). The ICER of belimumab compared to 
standard care was US$59,546 per life year and US$79,407 per QALY gained. Hong 
Kong’s GDP per capita is US$35,961. Thus, this result is within the WHO 
recommended threshold for cost-effectiveness, at 3 times GDP of US$107,883. 
CONCLUSIONS: This study shows that belimumab would be cost-effective 
compared to standard care for the treatment of SLE in Hong Kong.  
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OBJECTIVES: Hemophilia B is a rare condition and evidence of specific health 
and economic outcomes for it are relatively scarce. The purpose of this study 
was to assess economic and health consequences of prophylaxis vs on-demand 
supply of factor IX (FIX) in young patients diagnosed with moderate/severe 
hemophilia B, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model followed 
moderate/severe hemophilia B patients starting at age 2 until they reached 18 
years. Patients in prophylaxis received 64.6 IU recombinant FIX/kg per infusion 
and 2.77 infusions every two weeks (same dose used in spontaneous bleeds), 
while patients in the on-demand arm received 69.4 IU plasma-derived FIX/kg to 
manage spontaneous bleeds. A literature review for outcomes in hemophilia B 
was performed (rates of bleeding with prophylaxis and on-demand therapy, 
average doses). Weight and probability of death per age correspond to the 
Mexican population. Avoided bleeds were the effectiveness measure used. The 
model does not consider other costs than FIX acquisition costs and emergency 
room, which were extracted from IMSS´s sources (except the cost of recombinant 
FIX, provided by the manufacturer). Costs are expressed in 2012 US$. Costs and 
consequences were discounted at 5%/annum. Univariate sensitivity analysis was 
performed. RESULTS: The prophylaxis group experienced 49% fewer bleeds than 
the on-demand group (39.11 vs. 83.32 per patient, respectively), however, this is 
reached with an incremental cost of $817,818.89 (cost of prophylaxis was 
$920,411.15, almost nine times the cost of on-demand). In spite of this, ICER for 
prophylaxis was $18,500.63/avoided bleed. The model is highly sensitive to 
probability of spontaneous bleeding, doses and cost of acquisition of FIX. 
CONCLUSIONS: At IMSS, prophylaxis with recombinant FIX for the management 
of patients with moderate/severe hemophilia B would be an intervention with 
strong health benefits worth the additional investment required.  
 
PSY43  
ECONOMIC ASSESSMENT OF THE PROPHYLAXIS VERSUS ON-DEMAND 
APPROACH FOR THE TREATMENT OF HEMOPHILIA A IN YOUNG PATIENTS IN 
MEXICO  
Muciño-Ortega E1, Salinas-Escudero G2, Galindo-Suárez RM1 
1Pfizer S.A. de C.V., Mexico City, Mexico, 2Hospital Infantil de México Federico Gómez, Secretaría 
de Salud, Mexico City, Distrito Federal, Mexico  
OBJECTIVES: Hemophilia A is a disease with extreme disabling consequences. 
Prophylaxis helps to diminish them, but its cost should be assessed. The study 
was intended to estimate the economic and health consequences of prophylaxis 
vs on-demand supply of factor VIII (FVIII) in the management of patients with 
hemophilia A, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model simulated 
hemophilia in children from age 2 to 18 in two arms: prophylaxis with 
recombinant FVIII (25UI moroctocog alfa/kg every other day) and infusions of 
40UI/kg of plasma derived FVIII for spontaneous bleeds. The number of bleeds 
per approach, utilities and infusions required to control spontaneous bleeds 
were extracted from international literature. Both weight per age and probability 
of death were extracted from Mexican sources. Effectiveness measures were 
QALYs and bleeds avoided. The model assumed that safety and effectiveness 
profiles of both types of FVIII are equivalents, with no differences in costs of 
administration or adverse event management. Only the costs of acquisition of 
FVIII and emergency room were considered (both extracted from IMSS sources). 
Both costs and consequences were discounted at 5%/year. The costs are 
expressed in 2012 US$. Univariate sensitivity analysis was performed. RESULTS: 
There were 69% fewer bleeds in the prophylaxis group than in the on-demand 
group (50.7 vs 162.9, respectively), whereas the cost of prophylaxis represented 
5.6 times the cost of on-demand ($730,810 vs. $129,912, respectively), the ICER 
was $5,355.83/avoided bleed. Patients under prophylaxis gained 2.39 QALYs (9.88 
vs. 7.50), with an ICER of $251,876/QALY. The model is very sensitive to 
probability of spontaneous bleeding and dose in prophylaxis. CONCLUSIONS: 
From IMSS´s perspective, prophylaxis with moroctocog alfa for the management 
of patients with hemophilia A would bring highly valuable health benefits to 
patients, but more resources would need to be invested.  
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OBJECTIVES: Psoriasis is a chronic skin disease that strongly affects quality of 
life of its patients. In Ecuador, this disease affects 0.59% of the population and is 
estimated that 650 new patients are diagnosed every year with psoriasis 
according to the Ecuadorian National Foundation of Psoriasis. Biologic 
treatments had dramatically changed the therapeutics, outcomes and cost of 
management of these patients. The aim of this study is to assess the cost-
effectiveness of biologic alternatives available in Ecuador to treat moderate to 
severe psoriasis adult patients from a public payer’s perspective. METHODS: A 
decision-tree model was developed to simulate the clinical course of patients 
(18yrs+) treated with etanercept (50mg per week), adalimumab (80 mg on week 0, 
thereafter 40 mg every 2 weeks) and infliximab (5 mg/kg at weeks 0, 2, 6 and 
thereafter every 8 weeks) as first-line therapies, as well as treatment associated 
costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures 
were the percentage of patients reaching 75% improvement using the Psoriasis 
Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY´s). 
Costs considered included: biologic acquisition costs, concomitant medication, 
medical follow-up and side effects management. Clinical response of 
alternatives was extracted from published literature. Unit costs were collected 
from official Ecuadorian databases (Ministry of Health, National Social Security). 
RESULTS: After two years, the percentage of patients reaching PASI-75 were 
59.1%, 62.1% and 62.4% for adalimumab, etanercept and infliximab respectively 
(p=0.077, Friedman test). QALY´s associated to each alternative were: 1.50, 1.53 
and 1.53, respectively. Expected mean costs per patient were: US$ 66,240 for 
adalimumab; US$ 39,585 for etanercept and US$ 49,055.6 for Infliximab. These 
results were supported through probabilistic sensitivity analyses. 
CONCLUSIONS: In Ecuador, the less expensive therapy to treat moderate to 
severe adult psoriasis patients would be etanercept.  
 
PSY45  
COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE TREATMENT OF 
NEUROPATHIC PAIN IN COLOMBIA  
Ordoñez Molina JE1, Orozco Giraldo JJ1, Gutierrez-Ardila MV2 
1CES University, Medellin, Colombia, 2Pfizer S.A.S., Bogota, Colombia  
OBJECTIVES: Neuropathic pain is caused by various disorders affecting the 
central and peripheral nervous system. Its most common causes are secondary 
to herpes zoster infection and as a complication of diabetes mellitus. The aim of 
this analysis is to evaluate the cost-effectiveness of pregabalin versus duloxetine 
to estimate the pain reduction in diabetic neuropathy and postherpetic neuralgia 
from the social perspective in Colombia. METHODS: A Markov model was 
developed with 3 health-states: improvement (pain reduction >50% using visual 
analogue scale [VAS] against baseline), no improvement and treatment 
discontinuation (due to therapeutic failure). The time horizon is of 5 years (three-
month cycles) and discounts annually effectiveness and costs using a 3% rate. 
Comparators were pregabalin (150-300 mg/day) vs. duloxetine (60 mg/day). 
Population (>18 years) with neurophatic pain was estimated in 775,152 for 
Colombia. Effectiveness and utility data were taken from a literature and meta-
analysis of controlled clinical trials. Costs were taken from official tariff 
manuals, pricing laws and from the local health insurance company SURA. Costs 
are presented in 2012 USD. Effectiveness measure was Quality Adjusted Life 
Years (QALYs). RESULTS: Over a 5-year period, pregabalin obtained 231,105 
QALYs more than duloxetine (1,003,720 and 772,615 QALYs, respectively). Total 
expected savings with pregabalin was USD439.5M compared to duloxetine (total 
expected costs: USD664.8M and USD1,104.4M, respectively); costs for medical 
disabilities (sick leaves) were USD43.8 lower with pregabalin than duloxetine. 
Probabilistic sensitivity analyses showed the robustness of the model. 
CONCLUSIONS: Pregabalin is shown to be a cost-saving alternative compared 
with duloxetine for the treatment of neuropathic pain; pregabalin would have a 
higher rate of patients with reduction pain (51%) than duloxetine (41%), a larger 
number of QALYs and would have savings (USD567.1 per patient) due to lower 
costs of treatment and fewer payments for medical disabilities.  
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OBJECTIVES: Failed back surgery syndrome (FBSS) represents one main cause of 
chronic neuropathic or mixed pain. Clinical trials have shown that Spinal Cord 
